Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Breast cancer in systemic lupus erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer

    Research output: Contribution to journalReviewResearchpeer-review

  3. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.

METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.

RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6%) obtained a partial response, and 40 (63%) had stable disease.

CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.

Original languageEnglish
JournalOncology
Volume93
Issue number3
Pages (from-to)191-196
Number of pages6
ISSN0030-2414
DOIs
Publication statusPublished - 2017

    Research areas

  • Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Cetuximab, Colorectal Neoplasms, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Receptor, Epidermal Growth Factor, Retrospective Studies, Survival Rate, Treatment Outcome, Vascular Endothelial Growth Factor A, Journal Article

ID: 52652178